Feasibility Study of Intraperitoneal Bevacizumab for Palliation of Intractable Malignant Ascites
Status:
Terminated
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of intraperitoneal administration of
Bevacizumab to prevent the recurrence of malignant ascites. Ten patients will receive
intraperitoneal Bevacizumab 200 mg in 250 ml of normal saline for infusion every two weeks
for up to six weeks, or a maximum of three treatments.